Progressive Vaccinia Associated With Combined Variable Immunodeficiency

Keane, John T.

doi:10.1001/archderm.1983.01650290044015

Cited by 14 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, VIG treatment of progressive vaccinia is more successful in adults than children, because adults with acquired immunodeficiencies were likely less immunosuppressed than the children. With that said, there is a case report of an adult with combined variable immunodeficiency that survived progressive vaccinia after treatment with VIG and methisazone [45]. …”

Section: Vaccinia Immune Globulin (Vig)mentioning

confidence: 99%

Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections

Xiao

Isaacs

2010

Viruses

View full text Add to dashboard Cite

Despite the eradication of smallpox several decades ago, variola and monkeypox viruses still have the potential to become significant threats to public health. The current licensed live vaccinia virus-based smallpox vaccine is extremely effective as a prophylactic vaccine to prevent orthopoxvirus infections, but because of safety issues, it is no longer given as a routine vaccine to the general population. In the event of serious human orthopoxvirus infections, it is important to have treatments available for individual patients as well as their close contacts. The smallpox vaccine and vaccinia immune globulin (VIG) were used in the past as therapeutics for patients exposed to smallpox. VIG was also used in patients who were at high risk of developing complications from smallpox vaccination. Thus post-exposure vaccination and VIG treatments may again become important therapeutic modalities. This paper summarizes some of the historic use of the smallpox vaccine and immunoglobulins in the post-exposure setting in humans and reviews in detail the newer animal studies that address the use of therapeutic vaccines and immunoglobulins in orthopoxvirus infections as well as the development of new therapeutic monoclonal antibodies.

show abstract

Section: Vaccinia Immune Globulin (Vig)mentioning

confidence: 99%

Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections

Xiao

Isaacs

2010

Viruses

View full text Add to dashboard Cite

show abstract

Transient Decreases in Human T Cell Proliferative Responses Following Vaccinia Immunization

Mathew

Ennis

Rothman

2000

Clinical Immunology

View full text Add to dashboard Cite

Production and Characterization of Human Monoclonal Antibody Fab Fragments to Vaccinia Virus from a Phage-Display Combinatorial Library

et al. 1999

View full text Add to dashboard Cite

A combinatorial, phage-display library of human Fab antibody fragments was generated from IgG heavy chain (HC) and light chain (LC) genes cloned from the lymphocytes of a vaccinia virus (VACV)-immune donor. To ascertain the complexity of the library, nucleotide sequences of the variable regions of the HC and LC genes were determined. Fourteen distinct HC and 18 distinct LC (7 kappa and 11 lambda) that formed a combinatorial library of 22 Fabs were identified. Immune-precipitation of radiolabeled VACV revealed that at least six different VACV proteins were recognized by the antibodies. Plaque-reduction neutralization demonstrated that six of the Fabs neutralized VACV in the presence of anti-human antibody. ELISA studies indicated that 15 of the Fabs were cross-reactive with monkeypox virus.

show abstract

Progressive Vaccinia Associated With Combined Variable Immunodeficiency

Cited by 14 publications

References 22 publications

Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections

Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections

Transient Decreases in Human T Cell Proliferative Responses Following Vaccinia Immunization

Production and Characterization of Human Monoclonal Antibody Fab Fragments to Vaccinia Virus from a Phage-Display Combinatorial Library

Contact Info

Product

Resources

About